Score Overview
Explore the 2021 public Archive ranking →
Where Anika Therapeutics Inc has ranked, year by year
Showing 1 year ranking history by HDB Score.
Has not reached the top 50 on HDB Score in any year we have ranked.
- ANIK
1998: 10.1% · 2021: 57.3% · free through 2021 · longest runs
Net Income x Stock Price
Historical Returns
| Period | Price | Return |
|---|---|---|
Last Price2026-09-30 | $ 19.66 | — |
1 Year2025-09-30 | $ 9.40 | 109.15% |
5 Years2021-09-30 | $ 42.56 | -53.81% |
10 Years2016-09-30 | $ 47.85 | -58.91% |
20 Years2006-09-29 | $ 13.33 | 47.49% |
30 Years1996-09-30 | $ 5.75 | 241.91% |
| Period | Last Price2026-09-30 | 1 Year2025-09-30 | 5 Years2021-09-30 | 10 Years2016-09-30 | 20 Years2006-09-29 | 30 Years1996-09-30 |
|---|---|---|---|---|---|---|
| Price | $ 19.66 | $ 9.40 | $ 42.56 | $ 47.85 | $ 13.33 | $ 5.75 |
| Return | — | 109.15% | -53.81% | -58.91% | 47.49% | 241.91% |
Prices are split & dividend adjusted. All values are reported in USD.
Fundamental Data
Reported in USD
| Year | |||
|---|---|---|---|
| TTM | $ 120M | -$ 3M | $ 38M |
| 2025 | $ 112M | -$ 10M | $ 57M |
| 2024 | $ 119M | -$ 56M | $ 55M |
| 2023 | $ 120M | -$ 82M | $ 68M |
| 2022 | $ 156M | -$ 14M | $ 86M |
| 2021 | $ 147M | $ 4M | $ 94M |
| 2020 | $ 130M | -$ 23M | $ 98M |
| 2019 | $ 114M | $ 27M | $ 184M |
| 2018 | $ 105M | $ 18M | $ 159M |
| 2017 | $ 113M | $ 31M | $ 157M |
| 2016 | $ 103M | $ 32M | $ 124M |
| 2015 | $ 92M | $ 30M | $ 138M |
| 2014 | $ 105M | $ 38M | $ 106M |
| 2013 | $ 75M | $ 20M | $ 63M |
| 2012 | $ 71M | $ 11M | $ 44M |
| 2011 | $ 64M | $ 8M | $ 35M |
| 2010 | $ 55M | $ 4M | $ 28M |
| 2009 | $ 40M | $ 3M | $ 24M |
| 2008 | $ 35M | $ 3M | $ 43M |
| 2007 | $ 30M | $ 6M | $ 39M |
| 2006 | $ 26M | $ 4M | $ 47M |
| 2005 | $ 29M | $ 5M | $ 44M |
| 2004 | $ 26M | $ 11M | $ 39M |
| 2003 | $ 15M | $ 827K | $ 14M |
| 2002 | $ 13M | -$ 3M | $ 13M |
| 2001 | $ 11M | -$ 6M | $ 13M |
| 2000 | $ 16M | $ 173.55K | $ 18M |
| 1999 | $ 13M | -$ 2M | $ 14M |
| 1998 | $ 13M | $ 4M | $ 10M |
| 1997 | $ 12M | $ 3M | $ 22M |
| 1996 | $ 1M | -$ 2M | $ 2M |
| 1995 | $ 3M | -$ 2M | $ 2M |
| 1994 | $ 4M | -$ 1M | $ 2M |
| IPO1993 | $ 2M | -$ 1M | $ 5M |
Anika Therapeutics Inc fundamental performance
Between 2005 and 2025, revenue grew from $ 29M to $ 112M and net income went from $ 5M to -$ 10M. Revenue increased in 15 of those 20 years; net income in 13.
Across Anika Therapeutics Inc's full reported history, from 1993 to 2025, revenue grew from $ 2M to $ 112M and net income went from -$ 1M to -$ 10M. Revenue increased in 70% of the years measured; net income in 61%.
Anika Therapeutics Inc currently holds a 20-year HDB Score of 4.3 out of 10. How the HDB Score is calculated.
Membership
Continue ANIK’s history
The public Archive runs through 2021. Membership adds recent and current rankings.
- Recent and current rankings across 3,814 companies
- Compare companies with the latest data
- Track your research shortlist in a portfolio
